Armata Pharmaceuticals (ARMP) CBO awarded 183,142 stock options vesting 2027–2030

Rhea-AI Filing Summary

Armata Pharmaceuticals’ Chief Business Officer receives new stock option grant. On March 9, 2026, Pierre Kyme was granted stock options covering 183,142 shares of Armata Pharmaceuticals common stock at an exercise price of $11.6100 per share, expiring on March 9, 2036.

These options were awarded as a compensation grant and are held directly. According to the terms, 25% of the options vest on March 9 of each of 2027, 2028, 2029, and 2030, assuming continuous service through each vesting date. No open‑market purchases or sales were reported in this filing.

Insights

Equity compensation analyst

Routine option grant to Armata’s CBO, no share sale activity.

The Form 4 shows Chief Business Officer Pierre Kyme receiving 183,142 stock options with a strike price of $11.6100 and expiration in 2036. The code A identifies this as a grant or award, not a market trade.

Vesting is spread in four equal tranches on March 9 of 2027, 2028, 2029, and 2030, contingent on continuous service. This structure supports long-term retention and alignment but does not itself indicate a directional view on the stock.

No common-share purchases or sales accompany the grant, and derivativeSummary is empty aside from this award. The overall picture is a standard executive equity compensation event rather than a signal-driven insider trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kyme Pierre

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$11.61	03/09/2026		A		183,142		(1)	03/09/2036	Common Stock	183,142	$0.00	183,142	D

Explanation of Responses:

1. Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.

	/s/ Pierre Kyme	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Armata Pharmaceuticals (ARMP) report for Pierre Kyme?

Armata Pharmaceuticals reported that Chief Business Officer Pierre Kyme received a grant of 183,142 stock options on March 9, 2026. These options give him the right to buy common shares at a fixed exercise price, subject to future vesting conditions over several years.

What are the key terms of Pierre Kyme’s 183,142 Armata (ARMP) stock options?

The grant covers 183,142 stock options with an exercise price of $11.6100 per share and an expiration date of March 9, 2036. The options relate to Armata common stock and were awarded as a compensation grant held directly by the executive.

How do Pierre Kyme’s Armata (ARMP) stock options vest over time?

The options vest in four equal installments of 25% each on March 9 of 2027, 2028, 2029, and 2030. Vesting on each date requires Mr. Kyme to maintain continuous service with the company through that specific vesting date.

Did the Armata (ARMP) Form 4 show any stock sales or purchases by Pierre Kyme?

The Form 4 shows no open-market purchases or sales of Armata common stock by Pierre Kyme. It reports only a grant of stock options coded as an acquisition (A), with no accompanying dispositions or exercises of existing derivative or common share positions.

What is Pierre Kyme’s option position in Armata (ARMP) after this grant?

Following the transaction, Mr. Kyme holds 183,142 stock options as reported in the filing. These represent rights to acquire Armata common shares in the future, at the specified strike price, if and when the options vest and are exercised before expiration.

Why is Pierre Kyme’s Armata (ARMP) stock option grant significant for investors?

The grant shows Armata tying its Chief Business Officer’s compensation to long-term share performance through options vesting from 2027 to 2030. While routine, such equity awards can help align executive incentives with shareholder interests over the option term.